ストックスクリーナーアプリを入手
34.92
6.23%
-2.32
アフターアワーズ：
35.64
0.72
+2.06%
Bright Minds Biosciences Inc (DRUG) 最新ニュース
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March - The Manila Times
Can This CNS Drug Developer's Triple Conference Tour Spark Investor Interest? - StockTitan
How the (DRUG) price action is used to our Advantage - Stock Traders Daily
HC Wainwright Issues Negative Estimate for DRUG Earnings - Defense World
H.C. Wainwright maintains $85 target on Bright Minds stock By Investing.com - Investing.com Nigeria
H.C. Wainwright maintains $85 target on Bright Minds stock - Investing.com India
Bright Minds Biosciences (NASDAQ:DRUG) Given “Buy” Rating at HC Wainwright - Defense World
Bright Minds Biosciences’ BMB-101: A Promising Contender in Serotonergic Epilepsy Treatment with Strong Market Potential - TipRanks
Bright Minds Biosciences (NASDAQ:DRUG) Announces Earnings Results, Beats Estimates By $0.24 EPS - MarketBeat
Bright Minds Biosciences Dramatic Surge Highlights the High-Stakes Nature of Biotech Investments - HPBL
BriaCell Therapeutics: A Biotech Stock on the Brink of a Turnaround? - HPBL
Biotechs on the Brink: 2 Stocks With Huge Potential - Benzinga
Bright Minds Biosciences Shows Financial Improvement in Latest Report - TipRanks
When (DRUG) Moves Investors should Listen - Stock Traders Daily
SEC Form F-3 filed by Bright Minds Biosciences Inc. - Quantisnow
More Money In The Bank For Bright Minds Biosciences Insiders Who Divested CA$16m - Simply Wall St
How To Buy Bright Minds Biosciences Inc. Stock Online in February 2025 - Traders Union
Long Term Trading Analysis for (DRUG) - Stock Traders Daily
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101 - Seeking Alpha
Bright Minds Biosciences (NASDAQ:DRUG) Research Coverage Started at Piper Sandler - Defense World
Piper Sandler sets $93 target for Bright Minds Biosciences stock - MSN
Piper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight Recommendation - MSN
Piper Sandler sets $93 target for Bright Minds Biosciences stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald Predicts DRUG FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on DRUG FY2025 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Now Covered by Analysts at Piper Sandler - MarketBeat
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With - GlobeNewswire
Learn to Evaluate (DRUG) using the Charts - Stock Traders Daily
Bright Minds Biosciences Appoints New Chief Medical Officer to Advance CNS Therapeutics - MSN
Top 4 Canadian Biotech Stocks (Updated January 2025) - Investing News Network
Head-To-Head Analysis: Bright Minds Biosciences (NASDAQ:DRUG) versus Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Cantor Fitzgerald Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
HC Wainwright Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Bright Minds Biosciences Appoints Stephen Collins, M.D., Ph.D., as Chief Medical Officer - citybiz
Bright Minds Biosciences (NASDAQ:DRUG) Releases Earnings Results - MarketBeat
Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase - Nasdaq
(DRUG) Long Term Investment Analysis - Stock Traders Daily
Best-Performing Small-Cap Stocks of 2024 - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3% – Time to Sell? - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3%Time to Sell? - MarketBeat
(DRUG) Investment Analysis - Stock Traders Daily
Retail investors among Bright Minds Biosciences Inc.'s (CSE:DRUG) largest stockholders and were hit after last week's 10% price drop - Simply Wall St
Baird Initiates Coverage of Bright Minds Biosciences (DRUG) with Outperform Recommendation - MSN
Bright Minds Buosciences Surges 5,900% Last Week. Attention Turning To Cybin ($CYBN) Rallying 23% On Upcoming... - Daily Scanner
Bright Minds Biosciences (NASDAQ:DRUG) Raised to "Strong-Buy" at Baird R W - MarketBeat
3.13%
1.23%
大文字化:
|
ボリューム (24 時間):